Bausch Health Companies | VRX - Selling And Administration Expenses


Bausch Health Companies reported $901M in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
Amgen USD 1.72B 134M Jun/2026
ANI Pharmaceuticals USD 73.66M 9.14M Mar/2026
Aurora Cannabis CAD 41.4M 781K Mar/2026
Bausch Health Companies USD 901M 88M Jun/2026
Biogen USD 709.7M 155.4M Jun/2026
Bristol-Myers Squibb USD 1.83B 209M Jun/2026
Canopy Growth CAD 31.17M 2.27M Mar/2026
Corcept Therapeutics USD 156.9M 28.85M Jun/2026
Danaher USD 2.07B 212M Jun/2026
Drreddys Laboratories INR 14.47B 12.45B Mar/2026
Eli Lilly USD 3.43B 496M Jun/2026
Gilead Sciences USD 1.52B 70M Jun/2026
Nektar Therapeutics USD 11.87M 1.7M Mar/2026
Novo Nordisk DKK 16.31B 3.09B Jun/2026
Pacira USD 91.81M 7.93M Jun/2026
Perrigo USD 3.28B 3.02B Jun/2026
Phibro Animal Health USD 78.32M 10.24M Dec/2025
Prestige Brands USD 30.28M 606K Mar/2026
Supernus Pharmaceuticals USD 133.64M 15.41M Jun/2026
Vertex Pharmaceuticals USD 582.2M 88.5M Jun/2026
Zoetis USD 588M 31M Mar/2026